Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.52 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924688 | 0.88 | PTGES (0.53) | PTGESPLA2G4APPARG | |
| SCHEMBL4923430 | 0.78 | PTGES (0.45) | PTGESPLA2G4APPARGTP53 | |
| SCHEMBL4095879 | 0.77 | PPARG (0.43) | PPARG | |
| SCHEMBL4926553 | 0.77 | PTGES (0.41) | PTGESPPARGTP53POLBEDNRA | |
| SCHEMBL4916843 | 0.77 | MAPT (0.47) | PTGESEDNRA | |
| SCHEMBL333839 | 0.77 | PPARG (0.47) | PTGESPPARG | |
| SCHEMBL4925337 | 0.77 | PTGDR2 (0.40) | PTGESPPARG | |
| SCHEMBL4922258 | 0.76 | MAPT (0.47) | PTGESTP53EDNRA | |
| SCHEMBL4922669 | 0.76 | PTGDR (0.44) | PTGESPPARGEDNRBEDNRA | |
| SCHEMBL4922298 | 0.76 | PTGES (0.40) | PTGESPPARGEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | PTGES 35/4885PLA2G4A 1537/4885PPARG 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.